结构质谱在蛋白质治疗药物发现中的应用。

Structural mass spectrometry in protein therapeutics discovery.

机构信息

Gene Expression and Protein Biochemistry, Applied Biotechnologies, Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, USA.

出版信息

Anal Chem. 2010 Sep 1;82(17):7083-9. doi: 10.1021/ac101575d.

DOI:10.1021/ac101575d

PMID:20698501

Abstract

The protein therapeutics market is one of the highest growing segments of the pharmaceutical industry with an estimated global market value of $77 billion by 2011 (Global Protein Therapeutics Market report by RNCOS: Delhi, India, 2009). This growth has been fueled by several advantages that protein drugs can offer such as higher specificity, reduced side effects, and faster development time compared to small molecule drugs. Major pharmaceutical companies are strategically shifting gears toward protein therapeutics and gradually increasing the biologics portion of their pipelines. Consequently, in the present pharmaceutical industry, there is a rapid growth in the number and types of protein structural mass spectrometry analyses, particularly during the discovery phase where an abundance of new drug candidates are being investigated. This perspective article discusses the role of protein structural mass spectrometry during the discovery of protein therapeutics with focus on recombinant protein production quality control and structural biology applications. The current challenges in technologies associated with this field and the analytical prospects for the future direction will be also discussed.

摘要

蛋白质治疗药物市场是医药行业增长最快的领域之一，据估计，到 2011 年全球市场价值将达到 770 亿美元（印度德里 RNCOS 的《全球蛋白质治疗药物市场报告》，2009 年）。这种增长的动力来自于蛋白质药物相对于小分子药物所具有的一些优势，如更高的特异性、更低的副作用和更快的开发时间。大型制药公司正在战略性地转向蛋白质治疗药物，并逐渐增加其产品线中的生物制剂部分。因此，在当前的制药行业中，蛋白质结构质谱分析的数量和类型正在迅速增加，特别是在发现阶段，大量新的候选药物正在被研究。本文讨论了蛋白质结构质谱在蛋白质治疗药物发现中的作用，重点是重组蛋白生产质量控制和结构生物学应用。还讨论了该领域相关技术的当前挑战和未来发展方向的分析前景。